Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 254

1.

Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant.

Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M.

J Clin Psychiatry. 2004 Sep;65(9):1174-9.

PMID:
15367043
[PubMed - indexed for MEDLINE]
2.

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R.

J Clin Psychiatry. 1999 Jun;60(6):400-6.

PMID:
10401920
[PubMed - indexed for MEDLINE]
3.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
[PubMed - indexed for MEDLINE]
4.

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

Versiani M, Amin M, Chouinard G.

J Clin Psychopharmacol. 2000 Feb;20(1):28-34.

PMID:
10653205
[PubMed - indexed for MEDLINE]
5.

Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.

Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C.

Biol Psychiatry. 2007 Jul 1;62(1):65-71. Epub 2006 Dec 4.

PMID:
17141744
[PubMed - indexed for MEDLINE]
6.

[Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].

Eker SS, Akkaya C, Akgöz S, Sarandöl A, Kirli S.

Turk Psikiyatri Derg. 2005 Fall;16(3):153-63. Turkish.

PMID:
16180148
[PubMed - indexed for MEDLINE]
Free Article
7.

The antidepressant efficacy of reboxetine in patients with severe depression.

Montgomery S, Ferguson JM, Schwartz GE.

J Clin Psychopharmacol. 2003 Feb;23(1):45-50.

PMID:
12544375
[PubMed - indexed for MEDLINE]
8.

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.

Akkaya C, Sivrioglu EY, Akgoz S, Eker SS, Kirli S.

Hum Psychopharmacol. 2006 Jul;21(5):337-45.

PMID:
16856215
[PubMed - indexed for MEDLINE]
9.

Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.

Baldwin D, Bridgman K, Buis C.

J Psychopharmacol. 2006 Jan;20(1):91-6. Epub 2005 Oct 4.

PMID:
16204325
[PubMed - indexed for MEDLINE]
10.

Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.

Ferguson JM, Mendels J, Schwart GE.

Int Clin Psychopharmacol. 2002 Mar;17(2):45-51.

PMID:
11890185
[PubMed - indexed for MEDLINE]
11.

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK.

Arch Gen Psychiatry. 2006 Aug;63(8):856-64.

PMID:
16894061
[PubMed - indexed for MEDLINE]
12.

An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.

Carvalhal AS, de Abreu PB, Spode A, Correa J, Kapczinski F.

J Clin Psychiatry. 2003 Apr;64(4):421-4.

PMID:
12716244
[PubMed - indexed for MEDLINE]
13.

Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression.

Simpson GM, El Sheshai A, Rady A, Kingsbury SJ, Fayek M.

J Clin Psychiatry. 2003 Aug;64(8):959-65.

PMID:
12927014
[PubMed - indexed for MEDLINE]
14.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
[PubMed - indexed for MEDLINE]
15.

Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial.

Kennedy SH, Segal ZV, Cohen NL, Levitan RD, Gemar M, Bagby RM.

J Clin Psychiatry. 2003 Apr;64(4):439-44.

PMID:
12716247
[PubMed - indexed for MEDLINE]
16.

Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.

Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR.

Arch Gen Psychiatry. 2005 Feb;62(2):154-62.

PMID:
15699292
[PubMed - indexed for MEDLINE]
17.

Does the chronological relationship between the onset of dysthymia and major depression influence subsequent response to antidepressants?

Levitt AJ, Joffe RT, Sokolov ST.

J Affect Disord. 1998 Jan;47(1-3):169-75.

PMID:
9476757
[PubMed - indexed for MEDLINE]
18.

Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.

Grassi L, Biancosino B, Marmai L, Righi R.

J Clin Psychiatry. 2004 Apr;65(4):515-20.

PMID:
15119914
[PubMed - indexed for MEDLINE]
19.

A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.

DeMartinis NA, Yeung PP, Entsuah R, Manley AL.

J Clin Psychiatry. 2007 May;68(5):677-88.

PMID:
17503976
[PubMed - indexed for MEDLINE]
20.

An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.

Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M.

J Clin Psychiatry. 2005 Aug;66(8):1038-42.

PMID:
16086620
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk